SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients

Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) the presence of + myeloid cells demyelinating diseases. performed flow cytometry-based measurements expression on monocytes 86 MS patients, 41 NMOSD patients 31 healthy controls. Additionally, we histologically evaluated acute chronic brain lesions well other neurological found elevated 16/86 (18.6%) 4/41 (9.8%) patients. Almost all with high levels received exogenous interferon beta an immunomodulatory treatment only small fraction without had increased expression. In our cohort, was—apart from those receiving treatment—not significantly NMOSD, nor were associated more severe disease. abundantly present active range infectious malignant diseases central nervous system, but not lesions. The could be used investigate activity inflammatory CNS lesion.